Ken Griffin Kiniksa Pharmaceuticals, Ltd. Put Options Transaction History

Citadel Advisors LLC

7 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q1 2024 May 15, 2024	SELL	$17.63 - $21.74 $38,786 - $47,828	-2,200 Reduced 33.33%	4,400 $86,000
Q4 2023 Feb 14, 2024	SELL	$14.37 - $19.07 $159,507 - $211,677	-11,100 Reduced 62.71%	6,600 $115,000
Q3 2023 Nov 14, 2023	BUY	$13.62 - $20.2 $212,472 - $315,120	15,600 Added 742.86%	17,700 $307,000
Q2 2023 Aug 14, 2023	BUY	$10.44 - $16.48 $15,660 - $24,720	1,500 Added 250.0%	2,100 $29,000
Q1 2023 May 15, 2023	SELL	$10.7 - $15.79 $7,489 - $11,053	-700 Reduced 53.85%	600 $6,000
Q4 2022 Feb 14, 2023	SELL	$11.42 - $17.05 $226,116 - $337,590	-19,800 Reduced 93.84%	1,300 $19,000
Q3 2022 Nov 14, 2022	BUY	$9.76 - $13.41 $205,936 - $282,951	21,100 New	21,100 $271,000

1.95M

Ticker KNSA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 34,470,400
Market Cap $741M
Description
Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatm...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.